How Lipid Nanoparticles Work—Medicine's Tiny Couriers

The Envelope That Changed Medicine

Without lipid nanoparticles (LNPs), the mRNA revolution would never have left the laboratory. These microscopic fat bubbles — roughly 100 nanometers across, a thousand times smaller than a human hair — solve one of medicine's oldest problems: how to deliver fragile genetic instructions past the body's defenses and into living cells. Understanding how they work reveals why they have become the platform technology behind vaccines, gene therapies, and an expanding wave of next-generation medicines.

What Lipid Nanoparticles Are Made Of

Every LNP contains four key components, each with a specific job:

• Ionizable lipids — the core ingredient. At neutral pH they carry no charge, making them safe in the bloodstream. But inside the acidic environment of a cell's endosome, they become positively charged, enabling them to bind negatively charged mRNA and later escape the cellular compartment.
• Phospholipids — structural lipids that form the particle's outer shell, mimicking natural cell membranes.
• Cholesterol — fills gaps between lipids, stabilizing the particle and reducing leakage during transit.
• PEGylated lipids — polyethylene glycol–coated lipids that act as a stealth layer, preventing the immune system from destroying the particle before it reaches its target.

Together, these components self-assemble around a therapeutic payload — typically mRNA or small interfering RNA (siRNA) — forming a compact sphere that can survive the hostile environment of the bloodstream.

How They Enter Cells

Once injected, LNPs travel through tissue or blood until they encounter target cells. The particles are taken up through endocytosis — cells essentially swallow them into small membrane-bound compartments called endosomes. This is where the ionizable lipids earn their name: as the endosome's pH drops, the lipids acquire a positive charge that disrupts the endosomal membrane, releasing the mRNA cargo into the cell's cytoplasm.

This step — called endosomal escape — remains the biggest bottleneck in LNP technology. Studies estimate that only 1–2% of internalized nanoparticles successfully escape, which is why researchers continue to engineer better ionizable lipids and explore enhancers like amino acid supplements that can boost delivery up to 20-fold.

A 60-Year Journey

The road to modern LNPs began in the 1960s, when scientists discovered that lipids spontaneously form closed vesicles — liposomes — in water. In 1978, researchers first used liposomes to deliver mRNA into cells. But early formulations were unstable and triggered immune reactions.

The breakthrough came with the development of ionizable cationic lipids in the 2000s and 2010s, which remain neutral in the blood but activate inside cells. In 2018, the FDA approved Onpattro (patisiran), the first LNP-based drug, delivering siRNA to treat a rare nerve disorder. Two years later, both the Pfizer-BioNTech and Moderna COVID-19 vaccines used LNPs to deliver spike protein mRNA to billions of people worldwide.

Beyond Vaccines: The Next Frontier

LNPs are now being developed for applications far beyond infectious disease vaccines:

• Gene editing — LNPs deliver CRISPR components directly to target organs. In 2025, clinicians at the Children's Hospital of Philadelphia used LNP-delivered CRISPR to treat a newborn with a fatal metabolic disorder — the first personalized gene-editing therapy of its kind.
• Cancer immunotherapy — personalized cancer vaccines use LNPs to deliver mRNA encoding tumor-specific antigens, training the immune system to attack tumors.
• Rare genetic diseases — LNPs can deliver functional protein-coding mRNA to replace defective genes in conditions like cystic fibrosis.
• Cardiac repair — researchers are using LNPs to deliver VEGF-C mRNA to promote blood vessel growth after heart attacks.

Challenges Ahead

Despite their promise, LNPs face hurdles. Most formulations accumulate in the liver by default, making it difficult to target other organs like the brain or lungs. Cold-chain storage requirements add cost and logistical complexity. Repeated dosing can trigger immune responses against the PEG coating — a phenomenon called anti-PEG immunity — potentially reducing effectiveness over time.

Researchers are tackling these problems with machine learning–designed lipids, PEG alternatives, and ligand-targeted particles that home in on specific cell types. The goal is a universal delivery platform that can carry any genetic medicine to any tissue in the body.

From a laboratory curiosity in the 1960s to the backbone of a global vaccination campaign, lipid nanoparticles have proven that sometimes the envelope matters as much as the message inside.